About: Latamoxef

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Latamoxef Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections. [PubChem] (en)
http://linked.open...generalReferences	# Weitekamp MR, Aber RC: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983 Jan 7;249(1):69-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6217353 # Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M: Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986 Nov;146(11):2159-64. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3778044 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	1.6 hours (en)
http://linked.open...ugbank/indication	Latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins. It is used to treat bacterial infections. Latamoxef is primarily indicated in conditions like Bone and joint infection, GI infections, Gynecological infections, Meningitis, Respiratory tract infections, Septicaemia, Skin infections, Soft tissue infections, UTI. (en)
sameAs	Latamoxef
Title	Latamoxef (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/chebi/599928 http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/chemspider/43215 http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/drugbank/DB04570 http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/kegg-drug/D08109 http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/pubchem-compound/47499 http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/pubchem-substance/46505546 http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/pharmgkb/PA164743144 http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/wikipedia/Latamoxef
http://linked.open...mechanismOfAction	Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain (the penicillin-binding protein) by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that amoxicllin interferes with an autolysin inhibitor. (en)
http://linked.open...outeOfElimination	Renal Excretion accounts for 75 % (en)
http://linked.open.../drugbank/synonym	Latamoxef (en) moxalactam (en) Lamoxactam (en) LMOX (en) Latamoxefum (en) Oxa-cephem (en)
http://linked.open...drugbank/toxicity	Latamoxef produces potentially life-threatening effects which include Bleeding, Hypothrombinemia, Platelet dysfunctioning. which are responsible for the discontinuation of Latamoxef therapy. The symptomatic adverse reactions produced by Latamoxef are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Skin rashes, Hematuria, Hyperuricemia, Pyuria, Raised serum creatinine. (en)
http://linked.open...umeOfDistribution	8.51 L (en)
http://linked.open...nk/proteinBinding	40% (en)
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B3F4C-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B3F52-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B3F51-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B3F4E-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B3F4F-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B3F50-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B3F4A-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B3F48-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B3F4B-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B3F62-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B3F49-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Latamoxef
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B3F58-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B3F59-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B3F53-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B3F54-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B3F56-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B3F55-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B3F57-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Rapidly absorbed after oral administration. (en)
http://linked.open...casRegistryNumber	64952-97-2 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B3F5E-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B3F60-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B3F61-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B3F5D-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B3F5C-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B3F5F-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B3F4D-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B3F5A-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B3F5B-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 46 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software